Standard Biotools (LAB) Amortization of Deferred Charges (2017 - 2026)

Standard Biotools (LAB) has 10 years of Amortization of Deferred Charges data on file, last reported at $1.4 million in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 5.77% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $5.8 million, a 0.07% change from a year earlier, with the FY2023 full-year figure at $770000.0, down 7.23% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $1.4 million, down from $1.6 million in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for LAB reached as high as $1.6 million in Q3 2025 and fell as low as $173000.0 in Q4 2023.
• Historically, Amortization of Deferred Charges has averaged $782533.3 across 5 years, with a median of $212000.0 in 2022.
• Across the five-year window, Amortization of Deferred Charges tumbled 51.99% in 2022 and surged 648.13% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $202000.0 in 2022, then declined by 14.36% to $173000.0 in 2023, then soared by 708.67% to $1.4 million in 2024, then grew by 12.22% to $1.6 million in 2025, then slipped by 13.69% to $1.4 million in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $1.4 million in Q1 2026, $1.6 million in Q3 2025, and $1.4 million in Q2 2025.